Novel vaccine against dengue tested successfully in Switzerland

The results of a clinical study on a new type of vaccine that induces cellular immunity to combat dengue fever are positive and encouraging. Unisanté in Lausanne has conducted a clinical study on a new type of vaccine that induces cellular immunity to combat dengue fever. The results, published in The Lancet eBioMedicine, are positive and encouraging. Global warming and urbanisation are facilitating the spread of the tiger mosquito, responsible for dengue fever. The WHO estimates that almost half the world's population lives in high-risk areas, and cases of dengue fever have increased eightfold in 20 years. Having an effective vaccine is therefore a priority, Unisanté said in a press release on Monday. Two dengue vaccines are currently available in Europe, but they are proving unsatisfactory in terms of safety and efficacy. Their technology is based on the production of antibodies which, in certain cases, can increase the severity of the disease. This is why Unisanté has...